Cancer immunomics: From serological proteome analysis to multiple affinity protein profiling
Annals of the New York Academy of Sciences. 2007-06-01; 1107(1): 223-230
DOI: 10.1196/annals.1381.024
Lire sur PubMed
1. Ann N Y Acad Sci. 2007 Jun;1107:223-30.
Cancer immunomics: from serological proteome analysis to multiple affinity
protein profiling.
Hardouin J(1), Lasserre JP, Sylvius L, Joubert-Caron R, Caron M.
Author information:
(1)Protein Biochemistry and Proteomics Laboratory, CNRS UMR 7033 (BioMoCeti), UFR
SMBH Leonard de Vinci, University Paris13, 74, rue Marcel Cachin, 93017 Bobigny
cedex, France.
Cancer remains one of the leading causes of death worldwide. Thus, to identify
any useful biomarkers is still a need. We performed « cancer immunomics » to
identify autoantibody signatures produced in response to the presence of either
breast or colorectal cancer. SERological proteome analysis (SERPA) was performed
by two-dimensional (2-D) electrophoresis separation, immunoblotting, image
analysis, and mass spectrometry. Alternatively, to identify the antigens
recognized by the autoantibodies of cancer patients, we developed an approach
combining 2-D immunoaffinity chromatography, enzymatic digestion of the isolated
antigens, nano flow separation of the resulting peptides, and identification:
MAPPing (multiple affinity protein profiling). By these approaches we identified
both proteins recognized by autoantibodies independently of a cancer status, and
a limited number of proteins reacting preferentially with cancer sera.
DOI: 10.1196/annals.1381.024
PMID: 17804550 [Indexed for MEDLINE]